Este artigo é resultado da apresentação no I Seminário de Estudos em Análise de Discurso, realizado na Universidade Federal do Rio Grande do Sul, em 2003, tendo como ponto de análise o papel da memória segundo Michel Pêcheux.PALAVRAS-CHAVE: Memória. Formação discursiva. Discurso. História. Lingüística.RÉSUMÉCet article est résultat d’un travail présenté au I Séminaire d’Etudes en Analyse de Discours réalisé em 2003 à l’UFRGS ayant comme sujet le role de la mémoire à partir de Michel Pêcheux. MOTS-CLÉS: Mémoire. Formation discursive. Discours. Histoire. Linguistique.

Resumo: Nosso quadro teórico situa-se na sequência das reflexões propostas por Michel Pêcheux na França que ganharam um novo direcionamento no Brasil a partir dos estudos empreendidos por Eni Orlandi (Unicamp) e seu grupo de pesquisadores. A Análise de Discurso é marcada por uma dinâmica nova, assinalando outro tempo e revelando novas maneiras de ler as materialidades, o que se coloca como uma construção disciplinar bem específica no interior dos programas de formação de pesquisadores das principais universidades brasileiras. É sobre isso que nos propomos refletir, trazendo à baila noções tais como: constituição disciplinar, condições de produção, análise de discurso, memória. Palavras

No abstract

No abstract

<div>AbstractPurpose:<p>Nanoparticle-encapsulated drug formulations can improve responses to conventional chemotherapy by increasing drug retention within the tumor and by promoting a more effective antitumor immune response than free drug. New drug delivery modalities are needed in sarcomas because they are often chemoresistant cancers, but the rarity of sarcomas and the complexity of diverse subtypes makes it challenging to investigate novel drug formulations.</p>Experimental Design:<p>New drug formulations can be tested in animal models of sarcomas where the therapeutic response of different formulations can be compared using mice with identical tumor-initiating mutations. Here, using Cre/loxP and CRISPR/Cas9 techniques, we generated two distinct mouse models of <i>Pten</i>-deleted soft-tissue sarcoma: malignant peripheral nerve sheath tumor (MPNST) and undifferentiated pleomorphic sarcoma (UPS). We used these models to test the efficacy of chimeric polypeptide doxorubicin (CP-Dox), a nanoscale micelle formulation, in comparison with free doxorubicin.</p>Results:<p>The CP-Dox formulation was superior to free doxorubicin in MPNST models. However, in UPS tumors, CP-Dox did not improve survival in comparison with free doxorubicin. While CP-Dox treatment resulted in elevated intratumoral doxorubicin concentrations in MPNSTs, this increase was absent in UPS tumors. In addition, elevation of CD8⁺ T cells was observed exclusively in CP-Dox–treated MPNSTs, although these cells were not required for full efficacy of the CP nanoparticle–based chemotherapy.</p>Conclusions:<p>These results have important implications for treating sarcomas with nanoparticle-encapsulated chemotherapy by highlighting the tumor subtype–dependent nature of therapeutic response.</p></div>